IGC Pharma completes enrollment in Phase 2 CALMA Alzheimer’s agitation trial
Topline results are expected in Q4 2026. Final patient dosing is expected to finish in early November, followed by database lock and unblinding.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
POTOMAC, MD / / September 28, 2026 / IGC Pharma, Inc. AMEX:IGC ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia.CALMA achieved target enrollment with 168 participants…
IGC Pharma completes Phase 2 CALMA trial enrollment
Topline results for the Alzheimer's trial are expected in Q4 2026.